Last reviewed · How we verify
amoxicillin rifabutin
This is a combination of two antibiotics: amoxicillin inhibits bacterial cell wall synthesis, while rifabutin inhibits bacterial RNA polymerase to suppress protein synthesis.
This is a combination of two antibiotics: amoxicillin inhibits bacterial cell wall synthesis, while rifabutin inhibits bacterial RNA polymerase to suppress protein synthesis. Used for Bacterial infections susceptible to both amoxicillin and rifabutin (specific indications not clearly defined in available literature).
At a glance
| Generic name | amoxicillin rifabutin |
|---|---|
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Combination antibiotic (beta-lactam + rifamycin) |
| Target | Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that binds penicillin-binding proteins and disrupts peptidoglycan cross-linking in the bacterial cell wall, leading to cell lysis. Rifabutin is a rifamycin that binds bacterial RNA polymerase, blocking transcription and preventing bacterial protein synthesis. Together, they provide broad-spectrum coverage against various bacterial pathogens.
Approved indications
- Bacterial infections susceptible to both amoxicillin and rifabutin (specific indications not clearly defined in available literature)
Common side effects
- Diarrhea
- Nausea
- Rash
- Abdominal pain
- Uveitis (rifabutin-associated)
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Rescue Therapy for Helicobacter Pylori Infection (PHASE4)
- Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
- Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains (PHASE4)
- 14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection (PHASE4)
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori (NA)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amoxicillin rifabutin CI brief — competitive landscape report
- amoxicillin rifabutin updates RSS · CI watch RSS
- Shanghai Jiao Tong University School of Medicine portfolio CI